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rapid, direct measurement of diosmin in different pharmaceutical drugs. Conventional KBr-spectra
were compared for best determination of active substance in commercial preparations. The Beer–
Lambert law and two chemometric approaches, partial least squares (PLS) and principal compo-
nent regression (PCR+) methods, were tried in data processing.
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Infrared spectrometry (IR) provides a useful way for the iden-
tiﬁcation of drugs (USP XXII, 1990; Moffat, 1986; Ciurczak
and Drennen, 2001; McClure, 1992; Garrigues et al., 1992;678948; fax: +20 233370931.
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lsevierMiller et al., 1988) as well as for quantitative analysis, and
the help of Fourier transform (FT-IR) permits continuous
monitoring of the spectral baseline and simultaneous analysis
of different components of the same sample.
Diosmin (5-hydroxyl-2-(3-hydroxy-4-methoxy-phenyl)-4-
oxo-4H-chromen-7-yl or 30,5,7-trihydroxy-40-methoxyﬂavone-
7-rutinoside) is a naturally occurring ﬂavone glycoside, used
in the treatment of venous disease, i.e., chronic venous insufﬁ-
ciency (CVI) and hemorrhoidal disease (HD), in acute or
chronic hemorrhoids, in place of rubber-band ligation, in com-
bination with ﬁber supplement, or as an adjuvant therapy to
hemorrhoidectomy, in order to reduce secondary bleeding.
Diosmin is used widely in Europe for decreasing the appear-
ance of varicose veins and spider veins, and also hemorrhoids.
Diosmin and other ﬂavonoids thought to reduce capillary
304 A.A. Bunaciu et al.permeability and to have anti-inﬂammatory action, were collec-
tively known as vitamin P, but these substances, however, are
not vitamins.Hesperidin is the predominant ﬂavonoid in lemons
and oranges (Struckmann and Nicolaides, 1994). The peel and
membranous parts of these fruits have the highest hesperidin
concentrations.Hesperidine is classiﬁed as a citrus bioﬂavonoid.
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Chemometric techniques which are known as numerical
techniques are useful for the spectrophotometric resolution
of complex mixtures of analytes without the need of prior sep-
aration or extraction. Although both PCR and PLS give suc-
cessful results, they have several disadvantages such as using
abstract mathematical theory and various softwares.
Determination of the major component in drugs with FT-
IR spectrometry provides an enormous amount of spectro-
scopic information about a sample. Chemometric methods,
such as principal component regression (PCR+, improved
principal component regression) and partial least squares
(PLS2, multi-component partial least squares) analysis are
commonly used to extract the speciﬁc information relevant
to the analyte of interest from the full spectrum (USP XXII,
1990; Haleblian and McCrone, 1969). These two techniques
yields more accurate calibration models compared with multi-
ple linear regressions (MLR) where a restricted set of absorp-
tion bands is used in the calibration (Luinge et al., 1993). The
partial least squares (Projection to Latent Structures, PLS)
regression method was developed by Wold (1966). There is a
substantial amount of literature devoted to the theoretical elu-
cidation of properties of PLS algorithm. A good introduction
to the method is given by Geladi and Kowalski (1986).
The purpose of this study is the analysis of diosmin in phar-
maceutical formulation using FT-IR spectroscopy with the
application of Beer’s law and/or chemometric methods
(PCR+, PLS1 or PLS2), thus avoiding the sample pre-treat-
ment steps and providing the direct FT-IR measurement.2. Experimental
2.1. Apparatus
Data acquisition was performed using a Spectrum100 System
FT-IR spectrometer equipped with Spectrum for Windows
v.5.01 (Perkin–Elmer Co., Beaconsﬁeld, Bucks, UK). This soft-
ware also provided for a complete processing of the spectramea-
sured. For quantitative determination special softwares were
used, Spectrum Beer’s law and SpectrumQuant+, respectively.2.2. Reagents and materials
For fused KBr disk preparation, a potassium bromide IR spec-
tral grade was used (Sigma–Aldrich, Taufkirchen, Germany).The standard of diosmin was supplied by Fluka (Buchs,
Switzerland).
The pharmaceutical formulation Dioven 500 (containing
500 mg per tablet products) was obtained from Amriya Phar-
maceutical Industries International, Alexandria, Egypt.
2.3. Recommended procedures
Taking into consideration the heterogeneity of the specimens,
major attention was paid to the sampling stage. Drug sam-
ples were ground in a coffee grinder; ﬁner grinding and
homogenization with KBr were achieved by using a ‘vibrator’
ball mill (WIG-L-BUG). The temperature was kept around
25 C and the humidity was kept at a steady level in the
laboratory.
Conventional fused KBr disk spectra were recorded be-
tween 4000 and 350 cm1, by averaging 64 scans for each spec-
trum with a resolution of 4 cm1 (data point resolution/
interval 1 cm1) with a deuterated triglycine sulfate (DTGS)
detector. The samples were prepared by compressing 3.0 mg
of sample with spectral grade KBr, while the background
was spectral grade KBr. Each drug sample spectrum was col-
lected three times for the same cup after rotation 120. The
mean of the spectra, which were collected, was then used in
the following analysis steps.
For calibration, conventional fused KBr disk spectra
were recorded with a DTGS detector from samples prepared
by compressing a standard substance diosmin in spectral
grade KBr (calibration was made using ﬁve points 1.0, 1.
5, 2.0, 2.5 and 3.0 mg, respectively). The calibration
procedure is based on either a modiﬁed form of principal
component regression (PCR) or on a partial least squares
(PLS) ﬁt for one or more properties. The regression model
for each property is reﬁned by selecting only those factors
considered to be of statistical signiﬁcance in determining that
property.
Experimental parameters, such as calibration methods,
(PCR+, PLS1 or PLS2, respectively) were compared and
recommendations on the best options for diosmin analysis
were made.3. Results and discussion
Fig. 1 presents the mean spectra for diosmin samples using the
KBr disk method while the spectra of each pharmaceutical
drug are presented in Fig. 2.
It is of interest to note that in the ﬁngerprint region there
are no signiﬁcant differences between the spectra for KBr disk
method.
In PCR and PLS2, the spectra are modeled by one set of
factors and each property is modeled by relating the concen-
tration values to those factors. In PLS1, the spectra are mod-
eled by a different set of factors for each property and the
concentration values are modeled by the respective factors.
Hence PLS1 contains n separate calibrations, where n is the
number of properties in the method.
The calibrations of this study were carried out with the use
of the ‘expert’ option. The ﬁrst range used was between 4000
and 400 cm1 while the second range was 1570–1006 cm1.
In both cases no blanks were ﬁrst selected, but after calibration
was performed, the computer selects itself ranges of blanks due
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Figure 1 FT-IR spectra of diosmin – standard substance – in KBr-disk.
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Figure 2 FT-IR spectra of pharmaceutical products – in KBr-disk.
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is 4048 and 1319, respectively. The results are similar, as shown
in Table 1. We suggest the use of the PCR+ method, because
the peak to peak error value must be ﬁve times bigger thanroot mean square (RMS) error value at the most and the smal-
ler value of RSD (<3.0%).
We studied also the possibility to use the Beer–Lambert law
for the quantitative determination of diosmin in pharmaceuti-
Table 1 Comparison of the diosmin determination in tablets
using FT-IR chemometric approaches.
Dioven
PCR+ PLS
Content (mg/tablet) 505.23 509.13
RSD (%) (n= 5) 2.25 3.06
306 A.A. Bunaciu et al.cal formulation, but the measurements, could not be per-
formed because we do not ﬁnd a common baseline between
the spectra.
4. Conclusion
FT-IR spectrometry is capable for the analytical quantiﬁcation
of diosmin in pharmaceutical formulation. Commercial soft-
ware involving chemometric approaches, the method proposed
is simple, precise and not time-consuming compared to the
chromatographic methods that exist in literature. Quantiﬁca-
tion could be done in about 10–15 min, including sample prep-
aration and spectral acquisition.
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